Resource Hub
VIRTUAL TOUR
CONTACT US
Our Company
Investors
Services
Our Responsibility
Careers
Our Company
Investors
Services
Our Responsibility
Careers
© 2024 Aragen Bioscience. All rights reserved
Back
About Us
Our Journey
Leadership
Scientific and BD Team
Aragen Advantage
Investors
Global Locations
Media & Events
Recognitions
Disclosures under Regulation 62 of the LODR
Corporate Governance
Small Molecules
Large Molecules (Biologics)
Discovery
Aragen Integrated Drug Discovery (AIDD)
Integrated Drug Discovery
Chemistry
Biology
Safety Assessment
Development & Manufacturing
Drug Substance - new
Drug Substance
Drug Product
Analytical Development
Performance Chemicals
Custom Chemical Synthesis
Commercial Manufacturing
Discovery
Integrated Discovery
Molecular Biology
Antibody Discovery
Protein Sciences
Cell Line Development
Biology
Development & Manufacturing
Process Research & Development
Bioproduction
Developability & Analytics
GMP Manufacturing
EHS & Sustainability
Strategic Supply Chain Management
Quality
IP Protection & Data Security
Employee Welfare
Corporate Social Responsibility
Corporate Governance
Working at Aragen
Career Opportunities
Meet Our People
Caution Notice
Close Search
Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
GET IN TOUCH
Our Company
Resources
Resources
Resource Type
All
All
Articles
Brochures
Case Studies
On-demand Webinars
Posters
Whitepapers
Blogs
Virtual Tours
Videos
Filter by Science
All
All
Analytical
Biologics
Biology
Chemistry
Development
Ecotoxicology
Formulations BU
Intox
Manufacturing
NBEs Intox
PCET
SAS/Toxicology
Articles
View all
Solutions for Mitigating Challenges in Recombinant Protein Production
Preclinical Model of Post – Incisional Pain for Efficacy Testing of Novel Therapeutics
Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels
Clinically relevant preclinical model of CFA-Induced inflammatory pain
A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells
Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data
Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences
Aragen’s quantitative proteomics sampling capabilities: Accurate and Reproducible Workflows
Experimental pain models at Aragen Life Sciences – Spinal Nerve Ligation (SNL) Model of Neuropathic Pain
Pharmacokinetics (PK)/ Pharmacodynamics (PD) and Mechanistics solutions in Ellegaard Göttingen Minipigs
Comprehensive Characterization of Biologics
Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.
Automation to miniaturize
In vitro
assays to achieve superior and cost-efficient results
Targeted Protein Degradation
Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice
Cell line development capabilities
Cell line development comprehensive solutions
Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics
Industry Leading Hybridoma Technique for Accelerated Antibody Discovery
Covalent Drugs – Advantages, Challenges, And Opportunities
Mitigating CMC issues through Aragen’s holistic approach to developability assessment
Aragen’s Preclinical Oncology Capabilities – Tumor Imaging
Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models
Aragen’s Oncology solutions: Accelerate your cancer therapeutics development
RSV Challenge Model for anti-RSV therapy
Cell Line Development at Aragen: Research cell banks in 5 months
Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models
DSS-induced IBD Mouse Model for preclinical drug screening
Cell Line Development at Aragen; Accelerating speed to IND
View all
Brochures
View all
Your partner for timely, accurate and high-quality preclinical efficacy studies
Gene to GMP: First-in-human in 8 Months with Optimized Cost
Navigating Recombinant Protein Production– Leveraging Aragen’s Multifaceted Expression Systems
Modalities for Mechanistic Exploration in Agrochemical Solutions
Paclitaxel-induced Peripheral Neuropathic Pain Model Developed at Aragen
Comprehensive Services for Immersive Corrosion Testing of Metals and Alloys Across a Wide Spectrum of Test Subjects
Comprehensive
In-Vitro
Microbial Kill Rate Studies for screening antimicrobial agents
Exploring Molecular Interactions Through Surface Plasmon Resonance
Experimental λ-Carrageenan-induced inflammatory pain model for testing novel analgesics
Genetic and Alternative Toxicity Testing for Compound Screening, Derisking and Selection
Comprehensive Solutions for Animal Health Biologics
Aragen Cell Line Development Solutions for Biologics CHO CLD Platforms
Phosphonamidite
Oligonucleotides
Flow Chemistry
Specialized Services in Custom Peptide Synthesis (Solution Phase)
Comprehensive DoE capabilities for Synthesis, Process Development and Manufacturing of Novel Chemical Entities (NCE’s)
Nitrosamine Risk Assessment
Comprehensive GLP regulated Ecotoxicology Services
Comprehensive and Regulated “Developmental and Reproduction Toxicology (DART)” studies
Intox Safety Assessment
Preclinical Safety Evaluation and Clinical Bioanalysis Services for Vaccines
Nonclinical Safety Assessment of New Biological Entities (NBEs)
Process Safety, Dust Explosion Testing Capabilities
Aragen Overview
Your Partner for Chemocatalysis Solutions
Nonclinical Safety Assessment of New Chemical Entities (NCE)
Aragen protein science solutions: Industry leading upstream and downstream capabilities
Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
Biocatalysis Solutions
Streptozotocin-induced Diabetic Peripheral Neuropathic Pain Model Developed at Aragen
Targeted Protein Degradation Solutions
Aragen’s Preclinical Oncology Capabilities
Preclinical Evaluation of new Antifibrotics in IPF Rodent Models
Pharmacokinetic (PK) solutions in large animals
Formulation Solutions
Discovery Biology Solutions
ADME – DMPK Solutions
Extractables and Leachables Solutions
In Vitro
Pharmacology Solutions
In Vivo
Pharmacology Solutions
Nitrosamine Impurity Detection and Quantification
TOXVIT – Aragen
In Vitro
Toxicology Solutions
ICP-MS
Protein Analytics Solutions
Peptide Chemistry Solutions
API and Intermediates
Integrated Drug Discovery Solutions
Discovery Chemistry Solutions
Developability and Analytics Solutions
Contract Manufacturing Solutions
Integrated Cell Line Development Solutions
Small Molecule Process R&D and Manufacturing Solutions
Amylin Liver NASH (AMLN)
View all
Case Studies
View all
Redefine In silico Predictions with High-throughput LC-MS/MS LogD Analysis
Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model
Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification
A Preclinical Efficacy Study using Diet induced Obesity Mice Model
Designing an optimal and scalable protocol for formulating a 40% emulsifiable concentrate for a systemic insecticide
Developing a thermodynamically stable microemulsion with fine droplet size for delivering a highly lipophilic drug with limited intestinal permeability
Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors
Modelling Targeted Protein Degraders (TPDs) Utilizing Computational and Medicinal Chemistry Approaches
A robust and scalable strategy to develop monodisperse Nanosuspension formulation for a poorly soluble drug substance
A robust and scalable strategy to develop amorphous solid dispersion formulation for a poorly soluble drug substance
Comprehensive Preclinical Development Program for a COVID mRNA Vaccine
Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein
Alcoholic Steatohepatitis Model – CDAHFD
Consistency of Bleomycin-induced pulmonary fibrosis
Pro-inflammatory chemokines measured in bronchoalveolar lavage fluid (BALF)
Consistency of fibrotic induction in lungs from multiple studies
Non-Alcoholic Steatohepatitis Model
Treatment of CDAHFD-induced NASH mice with Elafibranor
Showing the readouts using the above-mentioned protocol
CS – Oncology 1
CS – Oncology 2
CS – Oncology 3
CS – Oncology 4
An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)
Enabling Formulation Development for Toxicology Studies for a New Chemical Entity
Physical Form Selection of a Small Molecule
View all
On-demand Webinars
View all
PROTACs: Breaking Boundaries in Drug Discovery
Process Development of New Chemical Entities — Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer
Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules
Accelerating Vaccines to Clinical Trials — A Toolkit for Efficacy, Safety and Bioanalytical Studies
Upstream Process Development for Better Yield and Product Quality
The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform
Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models
Development of Covalent Drugs with New Emerging Technologies
Accelerating Biologics Development to Medicines: Key Drivers of Success
Targeted Protein Degradation in Inflammation and Cancer Therapy
Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions
View all
Posters
View all
Therapeutic Impact of an ALK5 Inhibitor Across Multiple Preclinical Fibrosis Models
Enhancing mAb platform process using Membrane chromatography (Affinity/Protein-A, using Sartobind Rapid A) for FIH molecules with focus on Optimizing cost and Accelerating timelines
Decoding the Conformational Plasticity of Ternary Complexes for Protacs’ Differential Activity
In vitro
phototoxicity validation study
Reliable and Reproducible Preclinical Rodent Models of MAS
Phenotypic Characterization of Bleomycin-Induced Pulmonary Fibrosis Model
Column Head Loading in SFC
Blood Brain Permeability and CNS Bioavailability
In vitro/In vivo Correlation of Permeability
View all
Whitepapers
View all
Revolutionizing new drug discovery- Harnessing AI ML Tools
Preclinical Evaluation of Vaccines and Antivirals in RSV Challenge Rodent Models
Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models
Preclinical Evaluation of new Antifibrotics in Corona mouse Virus-Induced Fibrosis Model
Preclinical Evaluation of new Antifibrotics in IPF Rodent Models
Preclinical evaluation of vaccines and antivirals in RSV challenge SCID mouse models
Preclinical evaluation of vaccines and antivirals in RSV challenge in BALB/c Mouse models
Flow Chemistry vs. Batch Processes
A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform
A Highly Reproducible
In Vivo
Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis
Pharmacokinetic Strategies in CNS Drug Discovery
View all
Virtual Tours
View all
Discovery Chemistry
Analytical Chemistry
In Vitro
Pharmacology - Assay Development & Screening
In Vitro
Pharmacology - Toxicology
In Vivo
Pharmacology
DMPK
Cell and Protein Sciences
Process Safety
Analytical Development
Analytical Solutions
Formulation
Process Engineering
QC
Biologics
View all
Videos
View all
Aragen’s Kilo Lab
Analytical Research Facility
Manufacturing Unit at Hyderabad, India
Formulations Manufacturing Facility
Vivarium Facility at Bangalore, India
Discovery Biology R&D Facilities
Manufacturing Facility at Visakhapatnam, India
Discovery Chemistry Facilities
Tox Services – Capabilities and Infrastructure
Blogs
View all
What are peptides? Functions, Types & Synthesis Methods
Exploring Oligonucleotide Synthesis: A Catalyst for Precision Medicine, Gene Editing and Beyond
The Power of Integrated Drug Discovery Solutions: Enhancing Efficiency and Innovation in Drug Development
What is Pharmaceutical Formulation Development?
What are the Roles of Genomics and Proteomics in Drug Discovery and Personalized Medicine?
What is Structural Biology?
What is Medicinal Chemistry in Drug Discovery?
The Essential Role of Analytical Chemistry in the Pharmaceutical Industry
Overcoming Challenges in Chemical Engineering during Pharmaceutical Scale-Up
Optimizing Pharmaceutical Processes and Enhancing Biological Experimental Design Efficiency with Design of Experiments Methodology
The Role of Green Chemistry in Driving Success in Chemical Innovations
What is Lead Optimization in Drug Discovery?
What is Lead Identification in Drug Discovery?
What is High-Throughput Screening in Drug Discovery
What is Biologics Development?
Innovative Solutions: Overcoming Chemical Synthesis Hurdles in the Global CDMO Landscape
Navigating Growth: Challenges and Opportunities in the Small Molecule CDMO Sector
The Synergy of Services: How CDMOs Drive Innovation in Medicinal Chemistry?
CDMOs: Pioneering Partnerships in Immuno-Oncology Drug Development
What is Protein Science?
What is Antibody Discovery?
What is Molecular Biology?
What are Performance Chemicals?
The Rise of High Potent APIs: Trends, Technologies, and Manufacturing Best Practices
CDMO Innovations: Advancing Pharma Manufacturing with Chemical Development Solutions From Early To Late Phase
Maximizing Efficiency: How High-Throughput Screening Services Drive Drug Discovery
Streamlining Small Molecule Drug Development: The Advantages of Integrated CDMOs
Integrated Drug Discovery: Streamlining Therapeutic Solutions
Understanding Drug Safety and Efficacy: Key Concepts & Processes
What is Drug Interaction? Types, Symptoms, and Prevention
What Are Peptides – Their Functions, Advantages & Where Are They Used?
What’s Driving the Booming Market of Oligonucleotide Synthesis, Nationally and Globally
Why Integrated Service Offerings Matter in the Pharmaceutical Industry?
Biologics vs. Small Molecules: Critical Drug Development Insights
Reimagining Medicine with PROTACS – A Bold Vision for Future Therapies
Learn more about our end-to-end capabilities
×
Contact An Expert Today!
Contact Us
+
+